BIOLASE, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Concentrations

Concentrations

6 Months Ended

Jun. 30, 2016

Risks And Uncertainties [Abstract]

Concentrations

NOTE 10—CONCENTRATIONS

Revenue from the Company’s products for the three and six months ended June 30, 2016 and 2015 are as follows:

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2016			2015			2016			2015
Laser systems		70.7	%		65.6	%		67.0	%		65.1	%
Imaging systems		5.0	%		4.5	%		5.6	%		3.8	%
Consumables and other		12.5	%		15.9	%		14.1	%		16.7	%
Services		11.4	%		13.7	%		13.0	%		13.8	%
License fees and royalties		0.4	%		0.3	%		0.3	%		0.6	%
Total revenue		100.0	%		100.0	%		100.0	%		100.0	%

No individual customer represented more than 10% of the Company’s revenue for the three and six months ended June 30, 2016 or 2015.

The Company maintains its cash and cash equivalent accounts with established commercial banks. Such cash deposits periodically exceed the Federal Deposit Insurance Corporation insured limit.

As of June 30, 2016, one customer represented 10.5% of the Company’s accounts receivable. Amounts due are expected to be collected in full by the Company. No individual customer represented more than 10% of the Company’s accounts receivable at December 31, 2015.

The Company currently purchases certain key components of its products from single suppliers. Although there are a limited number of manufacturers of these key components, management believes that other suppliers could provide similar key components on comparable terms. A change in suppliers, however, could cause delays in manufacturing and a possible loss of sales, which could adversely affect the Company’s business, results of operations, and financial condition.